VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+25.35%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.91B
AUM Growth
+$1.91B
(+22%)
Cap. Flow
+$23.6M
Cap. Flow
% of AUM
1.23%
Top 10 Holdings %
Top 10 Hldgs %
65.6%
Holding
38
New
3
Increased
6
Reduced
6
Closed
–
Top Buys
| 1 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$54.4M |
| 2 |
ARTV
Artiva Biotherapeutics, Inc. Common Stock
ARTV
|
$24.9M |
| 3 |
CASI Pharmaceuticals
CASI
|
$5.39M |
| 4 |
enGene Holdings
ENGN
|
$4.88M |
| 5 |
Applied Therapeutics
APLT
|
$2.4M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$21.8M |
| 2 |
Merus
MRUS
|
$17.7M |
| 3 |
Zura Bio
ZURA
|
$16.2M |
| 4 |
Dianthus Therapeutics
DNTH
|
$9.58M |
| 5 |
Arvinas
ARVN
|
$4.27M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Financials | 0.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.17B
| $499M | 26.13% | 8,493,321 | – | – |
|
2
Ocular Therapeutix
OCUL
$2.12B
| $111M | 5.82% | 12,762,462 | – | – |
|
3
Enliven Therapeutics
ELVN
$1.2B
| $103M | 5.39% | 4,026,331 | – | – |
|
4
Viridian Therapeutics
VRDN
$1.5B
| $88.3M | 4.63% | 3,882,709 +38 | +0% | +$865 |
|
|
5
Applied Therapeutics
APLT
$71M
| $83.5M | 4.37% | 9,825,000 +282,129 | +3% | +$2.4M |
|
6
Spyre Therapeutics
SYRE
$996M
| $79M | 4.14% | 2,685,448 | – | – |
|
7
Dyne Therapeutics
DYN
$1.92B
| $78.1M | 4.09% | 2,173,913 | – | – |
|
|
ORKA
8
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $75.6M | 3.96% | 3,085,620 +2,219,245 | +256% | +$54.4M |
|
9
KalVista Pharmaceuticals
KALV
$678M
| $72.4M | 3.79% | 6,249,731 | – | – |
|
10
Pharvaris
PHVS
$1.39B
| $62.9M | 3.29% | 3,395,606 | – | – |
|
11
Cogent Biosciences
COGT
$1.69B
| $61.4M | 3.22% | 5,684,167 | – | – |
|
|
12
Dianthus Therapeutics
DNTH
$759M
| $47.8M | 2.5% | 1,744,373 -350,000 | -17% | -$9.58M |
|
13
4D Molecular Therapeutics
FDMT
$288M
| $47.6M | 2.49% | 4,400,000 | – | – |
|
|
14
Merus
MRUS
$4.98B
| $45.4M | 2.38% | 907,963 -355,251 | -28% | -$17.7M |
|
15
Oric Pharmaceuticals
ORIC
$994M
| $45M | 2.36% | 4,394,527 | – | – |
|
16
Erasca
ERAS
$445M
| $44.3M | 2.32% | 16,216,216 | – | – |
|
17
Praxis Precision Medicines
PRAX
$958M
| $40.6M | 2.13% | 706,131 | – | – |
|
18
Astria Therapeutics
ATXS
$349M
| $38.1M | 1.99% | 3,458,645 -150,000 | -4% | -$1.65M |
|
19
Terns Pharmaceuticals
TERN
$609M
| $28.4M | 1.49% | 3,410,058 | – | – |
|
20
Aquestive Therapeutics
AQST
$456M
| $27.7M | 1.45% | 5,555,555 | – | – |
|
|
21
Edgewise Therapeutics
EWTX
$1.51B
| $26.7M | 1.4% | 1,000,000 -818,182 | -45% | -$21.8M |
|
|
ARTV
22
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $24.9M | 1.3% | +1,609,569 | New | +$24.9M |
|
|
23
enGene Holdings
ENGN
$236M
| $23.5M | 1.23% | 3,565,841 +739,858 | +26% | +$4.88M |
|
24
Cullinan Oncology
CGEM
$445M
| $23.1M | 1.21% | 1,379,965 | – | – |
|
25
Mersana Therapeutics
MRSN
$36.5M
| $21.4M | 1.12% | 11,328,000 | – | – |
|